{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:05:10Z","timestamp":1780315510748,"version":"3.54.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2025.12.1001","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T23:40:04Z","timestamp":1767224404000},"page":"535-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous Stem Cell Transplantation for Multiple Sclerosis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0991-9506","authenticated-orcid":false,"given":"Shreya","family":"Condamoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1131-5564","authenticated-orcid":false,"given":"Pongthep","family":"Vittayawacharin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-0066","authenticated-orcid":false,"given":"Michael","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.12.1001_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis: a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1001_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0003","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ncl.2010.12.009","article-title":"The immunopathophysiology of multiple sclerosis","volume":"29","author":"Wu","year":"2011","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-030-19515-1_5","article-title":"Immune tolerance in autoimmune central nervous system disorders","author":"Jayaraman","year":"2019","journal-title":"Neuroimmune Dis"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0007","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.1001_bib0008","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J Exp Med"},{"issue":"20","key":"10.1016\/j.jtct.2025.12.1001_bib0009","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","article-title":"Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis","volume":"293","author":"Levin","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.1001_bib0010","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross-react with myelin antigens and co-produce IFN-gamma and IL-2","volume":"205","author":"L\u00fcnemann","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0011","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"issue":"34","key":"10.1016\/j.jtct.2025.12.1001_bib0012","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1001_bib0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.162.1.129","article-title":"EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis","volume":"162","author":"van Sechel","year":"1999","journal-title":"J Immunol"},{"issue":"Pt 9","key":"10.1016\/j.jtct.2025.12.1001_bib0014","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1001_bib0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ana.22609","article-title":"Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci","volume":"70","author":"Patsopoulos","year":"2011","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.1001_bib0016","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1101\/gr.264705.120","article-title":"Epstein-Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci","volume":"31","author":"Hong","year":"2021","journal-title":"Genome Res"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1001_bib0017","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/aje\/kwk118","article-title":"HLA-DR15 haplotype and multiple sclerosis: a HuGE review","volume":"165","author":"Schmidt","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.1001_bib0018","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study","volume":"357","author":"Hafler","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1001_bib0019","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","article-title":"HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis","volume":"183","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fimmu.2020.00781","article-title":"A brief review of the effects of vitamin D on multiple sclerosis","volume":"11","author":"Miclea","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0021","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1352458518801727","article-title":"Smoking and its interaction with genetics in MS etiology","volume":"25","author":"Hedstr\u00f6m","year":"2018","journal-title":"Mult Scler J"},{"issue":"19","key":"10.1016\/j.jtct.2025.12.1001_bib0022","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.cell.2022.08.021","article-title":"Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course","volume":"185","author":"Zhou","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1001_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.1001_bib0024","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.1001_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1001_bib0027","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7224\/1537-2073.2016-051","article-title":"A framework of care in multiple sclerosis, Part 1: updated disease classification and disease-modifying therapy use in specific circumstances","volume":"18","author":"Newsome","year":"2016","journal-title":"Int J MS Care"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4137\/PMC.S13213","article-title":"Multiple sclerosis: overview of disease-modifying agents","volume":"6","author":"Finkelsztejn","year":"2014","journal-title":"Perspect Medicin Chem"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian Population-Based Registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front Neurol"},{"issue":"10127","key":"10.1016\/j.jtct.2025.12.1001_bib0030","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1001_bib0031","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0032","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1001_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1703081","article-title":"Bone marrow transplantation for multiple sclerosis","volume":"16","author":"Burt","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.1001_bib0034","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1001_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0036","series-title":"Autologous Hematopoietic Cell Transplant for Patients With Multiple Sclerosis","author":"Tran","year":"2021"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.1001_bib0037","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.798300","article-title":"Haematopoietic stem cell transplantation results in extensive remodelling of the clonal T cell repertoire in multiple sclerosis","volume":"13","author":"Massey","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1001_bib0039","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200027","article-title":"B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"9","author":"von Niederh\u00e4usern","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1001_bib0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MS9.0000000000001490","article-title":"Immunological outcomes of autologous hematopoietic stem cell transplantation for multiple sclerosis: a systematic review","volume":"86","author":"Mrudula","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.1001_bib0041","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2003-03-0877","article-title":"Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores","volume":"102","author":"Burt","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.1001_bib0042","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16427","article-title":"Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis\u2014a systematic review","volume":"31","author":"Braun","year":"2024","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0043","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1001_bib0044","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jnnp-2020-323992","article-title":"Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing\u2013remitting multiple sclerosis: an observational study","volume":"92","author":"Zhukovsky","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1001_bib0046","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/acn3.51366","article-title":"aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis","volume":"8","author":"H\u00e4u\u00dfler","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1001_bib0047","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/ene.14324","article-title":"Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab","volume":"27","author":"Boffa","year":"2020","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.1001_bib0048","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.1001_bib0049","doi-asserted-by":"crossref","first-page":"e1215","DOI":"10.1212\/WNL.0000000000011461","article-title":"Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis","volume":"96","author":"Boffa","year":"2021","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.jtct.2025.12.1001_bib0050","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083582","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial","volume":"14","author":"Brittain","year":"2024","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1001_bib0052","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","article-title":"Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation","volume":"25","author":"Cohen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0053","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society","volume":"78","author":"Miller","year":"2021","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.1001_bib0054","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11910-023-01290-2","article-title":"Haematopoietic stem cell transplantation for the treatment of multiple sclerosis: recent advances","volume":"23","author":"Mariottini","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1001_bib0055","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciz047","article-title":"Epstein-Barr virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis","volume":"69","author":"Mehra","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109709","article-title":"Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis","volume":"254","author":"Massey","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1334720","article-title":"Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis","volume":"15","author":"Marti","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1001_bib0058","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"10044","key":"10.1016\/j.jtct.2025.12.1001_bib0059","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1001_bib0060","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/1352458506071301","article-title":"Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database","volume":"12","author":"Saccardi","year":"2006","journal-title":"Mult Scler J"},{"issue":"5A","key":"10.1016\/j.jtct.2025.12.1001_bib0061","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1083-8791(00)70066-8","article-title":"Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring","volume":"6","author":"Openshaw","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0062","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11899-019-00505-z","article-title":"Autologous haematopoietic stem cell transplantation in multiple sclerosis: a review of current literature and future directions for transplant haematologists and oncologists","volume":"14","author":"Das","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1001_bib0063","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00415-021-10820-2","article-title":"Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis","volume":"269","author":"Burt","year":"2022","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.1001_bib0064","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1177\/1352458514564484","article-title":"Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study","volume":"21","author":"Curro","year":"2015","journal-title":"Mult Scler J"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bmt.2009.127","article-title":"Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM\/horse ATG and CY\/rabbit ATG","volume":"45","author":"Hamerschlak","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0066","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s41409-024-02397-x","article-title":"BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis","volume":"59","author":"Silfverberg","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1001_bib0067","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp-2018-319446","article-title":"Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment-refractory multiple sclerosis","volume":"90","author":"Moore","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1001_bib0068","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol"},{"issue":"13","key":"10.1016\/j.jtct.2025.12.1001_bib0069","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1080\/10428194.2025.2547985","article-title":"Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma","volume":"66","author":"Chumnumsiriwath","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.1001_bib0070","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1212\/WNL.0000000000206750","article-title":"Hematopoietic stem cell transplantation in people with active secondary progressive multiple sclerosis","volume":"100","author":"Boffa","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0071","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1001_bib0072","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.27029","article-title":"The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases","volume":"96","author":"Brittain","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0073","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0074","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1001_bib0076","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.jtct.2025.12.1001_bib0077","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/bs.apha.2014.06.005","article-title":"Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies","volume":"71","author":"Stanimirovic","year":"2014","journal-title":"Adv Pharmacol"},{"issue":"24","key":"10.1016\/j.jtct.2025.12.1001_bib0078","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.1001_bib0079","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725027368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725027368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:08:55Z","timestamp":1780312135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725027368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636725027368"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.1001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous Stem Cell Transplantation for Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.1001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}